文献速递血液净化与透析水电解质与酸碱

口服呋塞米在血液透析患者中的疗效、安全性与耐受性:一项先导研究

Efficacy, Safety, and Tolerability of Oral Furosemide Among Patients Receiving Hemodialysis: A Pilot Study.
PubMed 文献 · Kidney Int Rep · 2022-07-12

该开放标签、单臂、18周剂量滴定先导研究评估口服呋塞米(最大剂量320 mg/天)在维持性血液透析且每日尿量至少1杯的患者中的疗效、安全性与耐受性。主要疗效结局为24小时尿量从基线增至预设阈值,第5、12、18周分别有12例(33%)、11例(33%)、7例(22%)达效(意向性分析)。呋塞米总体安全且耐受良好,但仅三分之一参与者第5周达效,疗效的临床重要性不确定。

要点

  • 口服呋塞米最大320 mg/天在血透患者中总体安全且耐受良好。
  • 第5周仅33%参与者达到尿量疗效定义,临床重要性不确定。
  • 未发生电解质、呋塞米水平或患者报告听力变化的安全事件。

核心结论

  • 呋塞米总体安全且耐受良好,但仅三分之一参与者在第5周达到疗效定义,疗效发现的临床重要性不确定。

研究设计与样本

  • 开放标签、单臂、18周剂量滴定先导研究,纳入维持性血液透析且每日尿量至少1杯的患者39例。
  • 口服呋塞米最大剂量320 mg/天。
  • 主要疗效结局为24小时尿量从基线增至预设阈值,阈值基于基线尿量(<200 ml/天 vs ≥200 ml/天)。
  • 安全性结局包括低钾血症和低镁血症,耐受性通过预设患者报告症状评估。

主要发现

  • 39例参与者中,28例(72%)接受预期呋塞米剂量,3例(8%)剂量减少,5例(12%)未减量即停药,3例(8%)减量后停药。
  • 基线24小时尿量中位数(四分位1,四分位3)为290 ml(110,740)。
  • 研究期间呋塞米最大平均日剂量范围为69 mg/天至320 mg/天。
  • 意向性分析中,第5、12、18周分别有12例(33%)、11例(33%)、7例(22%)达到尿量疗效结局。
  • 符合方案分析中,第5、12、18周分别有12例(39%)、9例(35%)、7例(28%)达到尿量疗效结局。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Diuretic use may reduce volume-related complications in hemodialysis. We evaluated the efficacy, safety, and tolerability of furosemide in patients with hemodialysis-dependent kidney failure. METHODS: We conducted an open label, single-arm, 18-week, dose titration pilot study of oral furosemide (maximum dose 320 mg/day) among patients receiving maintenance hemodialysis who reported at least 1 cup of urine output per day. The primary efficacy outcome was an increase from baseline to a specified threshold of 24-hour urine volume, with the threshold based on baseline urine volume (<200 ml/day vs. ≥200 ml/day). Safety outcomes included hypokalemia and hypomagnesemia, and tolerability was assessed by prespecified patient-reported symptoms. RESULTS: Of the 39 participants, 28 (72%) received the expected furosemide dose, 3 (8%) underwent dose reduction, 5 (12%) discontinued furosemide without dose reduction, and 3 (8%) underwent dose reduction and subsequently discontinued furosemide. The median (quartile 1, quartile 3) baseline 24-hour urine volume was 290 ml (110, 740), and the maximum, average daily study furosemide dose ranged from 69 mg/day to 320 mg/d. The urine output efficacy outcome was met by 12 (33%), 11 (33%), and 7 (22%) participants at weeks 5, 12, and 18, respectively, in the intention-to-treat analysis, and by 12 (39%), 9 (35%), and 7 (28%) participants at weeks 5, 12, and 18, respectively, in the on-treatment analysis. There were no electrolyte, furosemide level, or patient-reported hearing change safety events. CONCLUSION: Furosemide was generally safe and well tolerated, but only one-third of participants met the efficacy definition at week 5. The clinical importance of the efficacy findings is uncertain.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Flythe JE, Assimon MM, Tugman MJ, et al. Efficacy, Safety, and Tolerability of Oral Furosemide Among Patients Receiving Hemodialysis: A Pilot Study. Kidney Int Rep. 2022. PMID: 36217511. doi:10.1016/j.ekir.2022.07.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。